Key result
ESC Congress updates refine CV pharmacotherapy strategies in cardio-oncology and cardiac amyloidosis.
Expert review highlights advances in cardiovascular pharmacotherapy for cancer and amyloidosis patients, suggesting targeted strategies improve cardiac protection.
Massimiliano Camilli, Marianna Fontana, Pietro Ameri; Refining cardiovascular pharmacotherapy in cardio-oncology and cardiac amyloidosis: news from ESC Con
No takes yet. Share an insight, caveat, or question.
Camilli et al. (2026) studied this question. Cardiovascular pharmacotherapy strategies for cardio-oncology and cardiac amyloidosis are being refined based on new updates presented at the ESC Congress 2026.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: